Physician profile
Farooque Dastgir
NPI 1902053465
$4,430.22
in general payments reported to CMS, 2019-2025
25 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $128 · 2021: $520 · 2022: $716 · 2023: $645 · 2024: $918 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $39.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.29 |
| Education | $39.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,877.27 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Gilead Sciences, INC. | $527.34 | 2019-2025 | |
| Genzyme Corporation | $369.50 | 2023-2025 | |
| Janssen Biotech, INC. | $310.06 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $283.86 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $223.52 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $106.35 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.30 | 2019-2025 | Xifaxan |
| Vivus LLC | $83.31 | 2019-2021 | |
| Allergan, INC. | $77.00 | 2019-2020 | |
| Endogastric Solutions, INC | $72.44 | 2022 | |
| Madrigal Pharmaceuticals | $58.75 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $48.92 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $41.58 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $39.33 | 2021-2023 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $33.01 | 2025 | Vegzelma |
| Shionogi INC | $26.45 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.77 | 2023 | |
| Redhill Biopharma INC. | $21.69 | 2023 | Talicia, Aemcolo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.34 | 2023 | Cyltezo |
| Lilly USA, LLC | $20.25 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $18.36 | 2022 | |
| Ardelyx, INC. | $16.63 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $16.60 | 2021 | |
| Ucb, INC. | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farooque Dastgir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.